Shares of Revvity Inc. (RVTY) rallied over 6% in pre-market trading on Friday after the scientific instrument maker reported better-than-expected fourth-quarter earnings and issued an upbeat outlook for 2025.

For the fourth quarter, Revvity posted adjusted earnings per share from continuing operations of $1.42, up from $1.25 a year ago and beating analysts' estimates of $1.37. Revenue grew 5% year-over-year to $729.4 million, slightly ahead of expectations.

Both the Life Sciences and Diagnostics segments delivered solid organic revenue growth in Q4, with Life Sciences up 5% and Diagnostics rising 6% on an organic basis. However, foreign exchange headwinds weighed on reported revenue growth for the Diagnostics business.

Looking ahead, Revvity forecasts full-year 2025 adjusted EPS of $4.90 to $5.00 on revenue of $2.80 billion to $2.85 billion, compared to consensus estimates of $4.98 EPS on $2.86 billion in revenue. The company expects overall organic revenue growth of around 1% for the year, led by continued strength in Diagnostics.

"We finished last year on a strong note positioning us well as we head into 2025," said CEO Prahlad Singh. "I am confident that the full potential of Revvity will be even more externally apparent as we move through this year following the significant transformation our business has undergone."